The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the ongoing evolution in the healthcare sector to simplify patient treatment, Gilead and Merck announced successful 48-week results for a new once-weekly oral HIV regimen. According to reports, this collaboration between the pharmaceutical giants aims to provide a less frequent dosing alternative to traditional daily medications, potentially improving patient adherence and overall quality of life.
Data from the ISLEND-1 and ISLEND-2 trials demonstrated that the investigational combination of islatravir and lenacapavir maintained viral suppression at rates comparable to daily pills. Per market data, this clinical milestone comes as GILD shares closed at $133.21 and MRK shares closed at $124.41 on July 20, 2026.
Investors are now watching for upcoming regulatory submissions which could expand the market share for both mega-cap firms in the antiviral space. Based on the close of July 20, 2026, GILD is trading near its daily high of $135.5, while MRK remains within its daily range of $124.22 to $127.89.